Peter A. Thompson, a director, made two open market purchases of Edgewise Therapeutics ($EWTX) shares worth $10 million over the past year, with the latest on April 3, 2025. This ranks him 105th among 4,983 insiders, well above the $1.5 million average purchase value and 3.3 transactions. He sold Corvus Pharmaceuticals ($CRVS) shares once for nearly $4.9 million on June 27, 2025, ranking 1,970th. Thompson also sold Sionna Therapeutics ($SION) shares nine times for about $7.8 million, most recently on February 3, 2026, placing 1,384th out of 11,678 insiders versus the $8.6 million average and 6.4 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | S | Common Stock | 1890 | $44.57 | 3,559,765.0000 | 44,628,788 | 0.05% | 0.00% |
| Feb. 3, 2026 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | S | Common Stock | 29063 | $44.58 | 3,530,702.0000 | 44,628,788 | 0.82% | 0.07% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 30000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.04% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $2.12 | 8,819,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $1.64 | 8,804,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $2.49 | 8,789,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $0.97 | 8,774,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $0.99 | 8,759,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $2.60 | 8,744,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $2.74 | 8,729,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $3.27 | 8,714,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $2.00 | 8,699,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $3.61 | 8,684,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $12.50 | 8,669,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 15000 | $9.70 | 8,654,091.0000 | 82,836,369 | 0.17% | 0.02% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Common Stock | 30000 | $15.00 | 8,639,091.0000 | 82,836,369 | 0.35% | 0.04% |
| Jan. 28, 2026 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | M | Stock Option (Right to Buy) | 15000 | $0.00 | 0.0000 | 82,836,369 | 100.00% | 0.02% |
| Dec. 24, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | S | Common Stock | 33356 | $44.55 | 3,561,655.0000 | 44,628,788 | 0.93% | 0.07% |
| Dec. 18, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | S | Common Stock | 100 | $44.49 | 3,595,886.0000 | 44,628,788 | 0.00% | 0.00% |
| Dec. 17, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | S | Common Stock | 900 | $44.50 | 3,595,986.0000 | 44,628,788 | 0.03% | 0.00% |
| Dec. 19, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | S | Common Stock | 875 | $44.49 | 3,595,011.0000 | 44,628,788 | 0.02% | 0.00% |
| Nov. 26, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | S | Common Stock | 1600 | $44.49 | 3,596,886.0000 | 44,628,788 | 0.04% | 0.00% |
| Nov. 25, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | S | Common Stock | 11890 | $44.60 | 3,598,486.0000 | 44,628,788 | 0.33% | 0.03% |
| Nov. 24, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | S | Common Stock | 94583 | $44.54 | 3,610,376.0000 | 44,628,788 | 2.55% | 0.21% |
| June 27, 2025 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | S | Common Stock | 1176332 | $4.16 | 7,165,006.0000 | 75,152,514 | 14.10% | 1.57% |
| June 27, 2025 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | X | Common Warrants (right to buy) | 1397684 | $0.00 | 0.0000 | 75,152,514 | 100.00% | 1.86% |
| June 27, 2025 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | X | Common Stock | 1397684 | $3.50 | 8,341,338.0000 | 75,152,514 | 20.13% | 1.86% |
| June 25, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Thompson Peter A. | Not found | A | Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 102,390,828 | 9999.99% | 0.03% |
| June 16, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Thompson Peter A. | Not found | A | Stock Option (Right to Buy) | 30000 | $0.00 | 30,000.0000 | 95,130,053 | 9999.99% | 0.03% |
| June 12, 2025 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Not found | A | Stock Option (Right to Buy) | 15000 | $0.00 | 15,000.0000 | 75,152,514 | 9999.99% | 0.02% |
| June 12, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Director | A | Non-Qualified Stock Option (right to buy) | 19959 | $0.00 | 19,959.0000 | 0 | 9999.99% | 0.00% |
| April 3, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Thompson Peter A. | Director | P | Common Stock | 372578 | $20.13 | 14,809,075.0000 | 95,130,053 | 2.58% | 0.39% |
| April 3, 2025 | Edgewise Therapeutics, Inc. | $EWTX | Thompson Peter A. | Director | P | Common Stock | 124193 | $20.13 | 443,792.0000 | 95,130,053 | 38.86% | 0.13% |
| Feb. 10, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Not found | C | Series C convertible preferred stock | 2048760 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 10, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Not found | C | Series B convertible preferred stock | 2560951 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 10, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Not found | P | Common Stock | 550000 | $18.00 | 3,704,959.0000 | 0 | 17.43% | 0.00% |
| Feb. 10, 2025 | Sionna Therapeutics, Inc. | $SION | Thompson Peter A. | Not found | C | Common Stock | 3154959 | $0.00 | 3,154,959.0000 | 0 | 9999.99% | 0.00% |
| Aug. 26, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Thompson Peter A. | Director | S | Common Stock | 83695 | $13.00 | 8,288,510.0000 | 95,215,322 | 1.00% | 0.09% |
| Aug. 21, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Thompson Peter A. | Director | S | Common Stock | 394400 | $13.52 | 8,846,487.0000 | 95,215,322 | 4.27% | 0.41% |
| Aug. 21, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Thompson Peter A. | Director | S | Common Stock | 13300 | $14.61 | 8,833,187.0000 | 95,215,322 | 0.15% | 0.01% |
| Aug. 22, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Thompson Peter A. | Director | S | Common Stock | 391482 | $12.94 | 8,441,705.0000 | 95,215,322 | 4.43% | 0.41% |
| Aug. 23, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Thompson Peter A. | Director | S | Common Stock | 69500 | $13.03 | 8,372,205.0000 | 95,215,322 | 0.82% | 0.07% |
| June 20, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Thompson Peter A. | Not found | A | Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 95,215,322 | 9999.99% | 0.04% |
| June 13, 2024 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Not found | A | Stock Option (Right to Buy) | 15000 | $0.00 | 15,000.0000 | 49,038,582 | 9999.99% | 0.03% |
| June 10, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Thompson Peter A. | Not found | A | Stock Options (Right to buy) | 20594 | $0.00 | 20,594.0000 | 87,567,307 | 9999.99% | 0.02% |
| May 6, 2024 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | P | Common Warrants (right to buy) | 1397684 | $0.00 | 1,397,684.0000 | 49,038,582 | 9999.99% | 2.85% |
| May 6, 2024 | Corvus Pharmaceuticals, Inc. | $CRVS | Thompson Peter A. | Director | P | Pre-Funded Warrants (right to buy) | 1444085 | $1.73 | 1,444,085.0000 | 49,038,582 | 9999.99% | 2.94% |
| Jan. 23, 2024 | Edgewise Therapeutics, Inc. | $EWTX | Thompson Peter A. | Director | P | Common Stock | 454545 | $11.00 | 14,756,096.0000 | 63,723,600 | 3.18% | 0.71% |
| Aug. 29, 2023 | ARS Pharmaceuticals, Inc. | $SPRY | Thompson Peter A. | Director | P | Common Stock | 500000 | $6.20 | 9,240,887.0000 | 0 | 5.72% | 0.00% |
| June 27, 2023 | ARS Pharmaceuticals, Inc. | $SPRY | Thompson Peter A. | Director | A | Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |